US FDA Moves to Change Peptide Compounding Policy
The US Food and Drug Administration (FDA) has initiated steps to revise its policy on peptide compounding. This move aims to update regulations governing the preparation of peptide drugs, potentially impacting how these compounds are manufactured and distributed. The FDA's action reflects ongoing efforts to ensure safety and efficacy in pharmaceutical compounding practices.
Reuters·


